LUTS and Sexual Dysfunction: Implications for Management of BPH

European Urology, Supplement

Volumn 2, Issue 10, 2003, Pages 13-20

  Van Moorselaar, Jeroen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

5 reductase inhibitors; BPH; LUTS; Sexual dysfunction; 1 blockers

Indexed keywords

3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

AGING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MINIMALLY INVASIVE SURGERY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; URINARY TRACT DISEASE;

EID: 0346724256     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.11.004     Document Type: Conference Paper

References (47)

1. Andersson KE, Stief CG. Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol 1997:15(1): 14-20.
2. Anson K, Nawrocki J, Buckley J, Fowler C, Kirby R, Lawrence W, et al. A multicentre, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 1995;46:305-10.
3. Arai Y, Aoki Y, Okubo K, et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000;164:1206-11.
4. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5-alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19:413-25.
5. 1A-adrenoreceptor antagonist does not improve LUTS in men with BPH. J Urol 2002;167(Suppl):265.
6. Boon TA, van Swol CFP, van Venrooij GEPM, Beerlage HP, Verdaasdonk RM. Laser prostatectomy for patients with benign prostatic hyperplasia: a prospective randomized study comparing two different techniques using the Prolase-II fiber. World J Urol 1995; B:123-5.
7. Brookes ST, Donovan JL, Peters TJ, Abrahams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002;324:1059-65.
8. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997;31:272-80.
9. Choppin A, Blue DR, Hegde SS, Gennevois D, McKinnon SA, Mokatrin A, et al. Evaluation of oral ro-70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. Int J Impot Res 2001;13:157-61.
10. Cooper KL, McKiernan JM, Kaplan SA. α-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 1999;57:9-17.
11. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WPJ, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34:169-75.
12. Emberton M, Neal DE, Black N, et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol 1996;77:233-47.
13. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
14. Frankel SJ, Donovan JL, Peters TI, Abrams P, Dabhoiwala NF, Osawa D, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998;51:677-85.
15. 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 1995;116:1605-10.
16. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999;35:277-84.
17. Giuliano F, Allard F, McKenna K, Jardin A, Benoit G, Bernabe J. Tamsulosin has more deleterious effects than alfuzosin on parameters characterizing ejaculation in anaesthetized rats. Int J Impot Res 2002;14(Suppl 3):S12.
18. Hartung R, Emberton M, van Moorselaar RJA, Harving N, Matzkin H, Alcaraz A, Elhilali M, Vallancien G, and the Alf-One Study Group. Sexual dysfunction in 3,230 men with LUTS suggestive of BPH in Europe, Russia, the Middle East, Latin America and Asia. AUA 2003 [Abstract 1380].
19. Hendry B, Althof S, Benson GS et al. Male orgasmic and ejaculatory disorders. In: Jardin A, Wagner S, Koury S, et al., editors. Erectile Dysfunction. Plymouth (UK): World Health Organization Publication 2000; pp. 477-506.
20. Höffner K, Claes H, De Reijke TM, et al. for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41.
21. 1-adrenoceptor antagonist R-(-)-YM12617 on isolated human penile erectile tissue and vas deferens. Eur J Pharmacol 1990;186:87-93.
22. Kabalin JN, Gill HS, Bite G, Wolfe V. Comparative study of laser versus electocautery prostatic resection: 18-month follow up with complex urodynamic assessment. J Urol 1995;153:94-7.
23. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Proscar Long-term Efficacy and Safety Group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001;57:1073-7.
24. 1L-adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br J Pharmacol 1998;123:1359-66.
25. Keoghane SR, Doll HA, Lawrence KC, Jenkinson CP, Cranston DW. The Oxford laser prostate trial: sexual function data from a randomized controlled trial of contact laser prostatectomy. Eur Urol 1996;30:424-8.
26. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB for the PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) Trial. Urology 2003;61:119-26.
27. Kunelius P, Hakkinen J, Lukkarinen O. Sexual functions in patients with benign prostatic hyperplasia before and after transurethral resection of the prostate. Urol Res 1998;26:7-9.
28. Larson TR. Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology 2003;61:692-8.
29. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley R for the Veterans' Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-9.
30. Lepor H for the Tamsulosin Investigator Group. Phase III multicenter, placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
31. Lepor H for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998;51:901-6.
32. Mann T, Lutwak-Mann C. Male reproductive function and semen. Berlin: Springer-Verlag; 1981. p. 171-93.
33. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
34. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001;57:466-70.
35. Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003;91:873-7.
36. Ramirez-Gil JE, Pouyet T, Mayoux E, Galzin AM, Arbilla S. Enhancement by alfuzosin of the proerectile properties of apomorphine in SHR rats. J Urol 2002;167(Suppl):281.
37. Roehrborn CG. Standard surgical interventions: TURP/TUIP/OPSU. In: Kirby R, McConnell J, Fitzpatrick J, et al., editors. Textbook of benign prostatic hyperplasia. Oxford: ISIS Medical Media; 1996. p. 341-78.
38. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001;58:953-9.
39. Roehrbom CG, Boyle P, Nickel JC, Hoefner K, Andriole G on behalf of the ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
40. Rosen RC, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Ageing Male (MSAM-7). Eur Urol 2003;44:637-49.
41. 1-adrenoreceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994;261:59-64.
42. Sells H, Donovan J, Ewings P, Macdonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000;85:440-5.
43. Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis 2001;4(S1):S12-6.
44. Silva MA, Megale A, Avellar MC, Porto CS. Expression and pharmacological characterization of alpha1-adrenoceptors in rat seminal vesicle. Eur J Pharmacol 1999;381:141-9.
45. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000;37:306-13.
46. van Kerrebroeck P, Jardin A, van Cangh P, Laval KU the ALFORTI Study Group. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002;41:54-61.
47. van Moorselaar RJA, Emberton M, Harving N, Matzkin H, Hartung R, Alcaraz A, Elhilali M, Vallancien G for the ALFONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with LUTS and concomitant sexual dysfunction. Eur Urol Suppl 2003;2(1):74 [Abstract 285].